Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    ISSN: 1432-1335
    Keywords: Key words Malignant melanoma ; S100β protein ; Tumour markers
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract S100 protein is well established as a diagnostic tool in malignant melanoma immunohistology. In this study we measured S100β in serum with a recently developed luminometric immunoassay with a detection limit of 0.02 μg/l. By measuring S-100β in a group of apparently healthy individuals a mean value of 0.031 ± 0.026 μg/l was found. In the reference group, serum S100β was below 0.12 μg/l in all cases. To assess the sensitivity of the assay we investigated serum S-100β levels in 371 serum samples of 315 patients with histological proven malignant melanoma at different disease stages. Staging was performed according to the German Society of Dermatology classification. Significant differences were observed between the control group and stages IIb (P = 0.01) and IV (P = 0.001). In tumour-bearing patients of stages IIIb and IV, the difference was highly significant (P 〈 0.0001). S100β 〉 0.20 μg/l helps to distinguish between tumour-free and tumour-bearing patients with a specificity of 97.0% and a sensitivity of 64.6%. Our results demonstrate the serum S100β is of limited value as a melanoma marker. However, it has clinical significance for identifying tumour-positive patients in advanced malignant melanoma stages III and IV.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...